Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lowered its stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Rating) by 57.6% during the third quarter, HoldingsChannel reports. The firm owned 88,172 shares of the specialty pharmaceutical company’s stock after selling 119,997 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Eagle Pharmaceuticals were worth $2,329,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. BlackRock Inc. lifted its position in shares of Eagle Pharmaceuticals by 0.7% in the first quarter. BlackRock Inc. now owns 1,982,333 shares of the specialty pharmaceutical company’s stock valued at $98,105,000 after acquiring an additional 13,517 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Eagle Pharmaceuticals by 2.7% in the first quarter. Vanguard Group Inc. now owns 780,851 shares of the specialty pharmaceutical company’s stock valued at $38,644,000 after acquiring an additional 20,383 shares in the last quarter. State Street Corp lifted its position in shares of Eagle Pharmaceuticals by 8.4% in the second quarter. State Street Corp now owns 775,860 shares of the specialty pharmaceutical company’s stock valued at $34,471,000 after acquiring an additional 59,976 shares in the last quarter. Millennium Management LLC lifted its position in shares of Eagle Pharmaceuticals by 2,428.4% in the second quarter. Millennium Management LLC now owns 314,739 shares of the specialty pharmaceutical company’s stock valued at $13,984,000 after acquiring an additional 302,291 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Eagle Pharmaceuticals by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 304,784 shares of the specialty pharmaceutical company’s stock valued at $15,084,000 after acquiring an additional 15,055 shares in the last quarter. Institutional investors and hedge funds own 88.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, November 11th.

Eagle Pharmaceuticals Stock Performance

Eagle Pharmaceuticals stock opened at $33.37 on Friday. The firm has a market capitalization of $434.34 million, a P/E ratio of 17.38 and a beta of 0.88. The stock has a fifty day moving average price of $32.57 and a 200 day moving average price of $33.95. Eagle Pharmaceuticals, Inc. has a 52 week low of $24.35 and a 52 week high of $53.78. The company has a current ratio of 1.52, a quick ratio of 0.99 and a debt-to-equity ratio of 0.11.

Eagle Pharmaceuticals (NASDAQ:EGRX – Get Rating) last released its earnings results on Monday, November 7th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.23 by ($0.50). The business had revenue of $65.90 million during the quarter, compared to analyst estimates of $59.37 million. Eagle Pharmaceuticals had a net margin of 8.35% and a return on equity of 11.55%. Equities research analysts anticipate that Eagle Pharmaceuticals, Inc. will post 1.94 earnings per share for the current year.

Eagle Pharmaceuticals Company Profile

(Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.